Fundraising Fox

Sofinnova Ventures2023 Investments

3 investments dated 2023 · listed companies and verified rows first · show all

Adaptive Phage TherapeuticsJun 2023SEC filingmedium confidence

BiotechGaithersburg, US

Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)

BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)

Board seatJonathan Leff· per SEC Form D · $30M raise · filed Jun 2023

Co-investorsAMR Action Fund

Genoa Pharmaceuticalsgenoa-pharmaceuticals.appspot.comOct 2023SEC filingmedium confidence

Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

BiotechHealthtechSan Diego, US

Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)

BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)

Board seatJonathan Leff· per SEC Form D · $189.2M raise · filed Oct 2023

Co-investorsNorwest Venture PartnersRiverVest Venture Partners

Rarecyterarecyte.comJul 2023SEC filingmedium confidence

Seattle, US

Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)

BoardRobert Shepler(Director)in

Board seatDavid Kabakoff· per SEC Form D · $35.7M raise · filed Jul 2023

Co-investors5AM VenturesArboretum VenturesF-Prime CapitalTelegraph Hill Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.